Occlusive Spasm of the Left Anterior Descending Artery and First Diagonal Branch After Implantation of Everolimus Eluting Stents Without Re-stenosis in a Female Patient with Resting Angina

Occlusive Spasm of the Left Anterior Descending Artery and First Diagonal Branch After Implantation of Everolimus Eluting Stents Without Re-stenosis in a Female Patient with Resting Angina

Bibliographic Details
Main Authors:	Giancarlo Pirozzolo, Anastasios Athanasiadis, Udo Sechtem, Peter Ong
Format:	Article
Language:	English
Published:	Compuscript Ltd 2017-04-01
Series:	Cardiovascular Innovations and Applications
Online Access:	https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2017.0016

Similar Items

Persisting Angina after Successful Surgical Removal of a Large Coronary Artery Aneurysm Attached to the Proximal Portion of the Left Circumflex Artery: Role of Coronary Artery Spasm
by: Udo Sechtem, et al.
Published: (2018-06-01)

Prevention of epicardial coronary artery spasm with intracoronary nitroglycerine during acetylcholine testing in a female patient with resting angina—implications for optimal pharmacological management
by: Valeria Martínez Pereyra, et al.
Published: (2022-03-01)

Everolimus-eluting coronary stents
by: Alejandro Saez, et al.
Published: (2010-09-01)

Everolimus-eluting stents in interventional cardiology
by: Townsend JC, et al.
Published: (2012-06-01)

Everolimus-eluting stents versus sirolimus-eluting stents in patients with cardiac allograft vasculopathy
by: Michał Hawranek, et al.
Published: (2021-12-01)

A meta-analysis of everolimus-eluting stents versus sirolimus-eluting stents and paclitaxel-eluting stents in diabetic patients
by: Hang Ouyang, et al.
Published: (2021-04-01)

Second Generation Drug-Eluting Stents: A Review of the Everolimus-Eluting Platform
by: Matthew G. Whitbeck, et al.
Published: (2013-01-01)

Second Generation Drug-Eluting Stents: A Review of the Everolimus-Eluting Platform
by: Matthew G. Whitbeck, et al.
Published: (2013-07-01)

Repurposing Riociguat for Treatment of Refractory Angina Resulting From Coronary Spasm
by: Valeria Martínez Pereyra, MS, et al.
Published: (2021-03-01)

Everolimus-eluting stents: update on current clinical studies
by: Allocco DJ, et al.
Published: (2011-07-01)

Clinical results of everolimus-eluting stents and sirolimus-eluting stents in patients undergoing percutaneous coronary intervention
by: Iraj Jafaripour, et al.
Published: (2023-05-01)

Two-year results of an open-label randomized comparison of everolimus-eluting stents and sirolimus-eluting stents.
by: Matthijs A Velders, et al.
Published: (2014-01-01)

Correction: Two-Year Results of an Open-Label Randomized Comparison of Everolimus-Eluting Stents and Sirolimus-Eluting Stents.
by: Matthijs A. Velders, et al.
Published: (2013-01-01)

The Twelve-Month Outcome of Biolimus Eluting Stent with Biodegradable Polymer Compared With an Everolimus Eluting Stent with Durable Polymer
by: Ahmad Separham, et al.
Published: (2011-11-01)

Correction: Two-Year Results of an Open-Label Randomized Comparison of Everolimus-Eluting Stents and Sirolimus-Eluting Stents
Published: (2013-01-01)

Case series of coronary artery aneurysms after Everolimus eluting stent implantation and comparison with Sirolimus eluting stents
by: Raghav Sharma, et al.
Published: (2022-02-01)

Clinical outcome of biodegradable polymer sirolimus-eluting stent and durable polymer everolimus-eluting stent in patients with diabetes
by: Ryota Kakizaki, et al.
Published: (2020-10-01)

Study to assess clinical outcomes of an everolimus-eluting stent (EES) versus a sirolimus-eluting stent (SES)
by: Amit Madaan, et al.
Published: (2015-12-01)

Vascular response to everolimus- and biolimus-eluting coronary stents versus everolimus-eluting bioresorbable scaffolds – an optical coherence tomography substudy of the EVERBIO II trial
by: Zacharenia Kallinikou, et al.
Published: (2016-01-01)

Comparison of the everolimus-eluting bioresorbable vascular scaffold versus the everolimus-eluting metallic stent in real-world patients with ST-segment elevation myocardial infarction
by: Piotr Desperak, et al.
Published: (2020-04-01)

Effects of Everolimus-Eluting Stents on the Left Ventricular Systolic and Diastolic Functions
by: MohammadSadegh Parsaee, et al.
Published: (2015-10-01)

Biodegradable polymer everolimus-eluting stents versus contemporary drug-eluting stents: a systematic review and meta‑analysis
by: Juntao Yin, et al.
Published: (2023-01-01)

Next-generation drug-eluting stents in coronary artery disease: focus on everolimus-eluting stent (Xience V®)
by: Imad Sheiban, et al.
Published: (2008-02-01)

One-Year Outcome of Everolimus-Eluting Stents versus Biolimus-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention
by: Mohammad Alidoosti, et al.
Published: (2016-10-01)

Clinical outcomes of biodegradable polymer biolimus-eluting BioMatrix stents versus durable polymer everolimus-eluting Xience stents.
by: Da Hyon Lee, et al.
Published: (2017-01-01)

Everolimus-eluting stents or bypass surgery for left main coronary artery disease.
by: Stone, GW, et al.
Published: (2016)

Everolimus-Eluting Stents Reduce Monocyte Expression of Toll-Like Receptor 4
by: Mehriar Shokri, et al.
Published: (2015-12-01)

Everolimus-eluting stent platforms in percutaneous coronary intervention: comparative effectiveness and outcomes
by: Panoulas VF, et al.
Published: (2015-07-01)

Computational and experimental mechanical performance of a new everolimus-eluting stent purpose-built for left main interventions
by: Saurabhi Samant, et al.
Published: (2021-04-01)

A novel platinum chromium everolimus-eluting stent for the treatment of coronary artery disease
by: Bennett J, et al.
Published: (2013-06-01)

The everolimus-eluting Xience stent in small vessel disease: bench, clinical, and pathology view
by: Sanchez OD, et al.
Published: (2014-12-01)

Five‐Year Outcomes in Patients With Diabetes Mellitus Treated With Biodegradable Polymer Sirolimus‐Eluting Stents Versus Durable Polymer Everolimus‐Eluting Stents
by: Juan F. Iglesias, et al.
Published: (2019-11-01)

Outcomes of patients treated with the everolimus-eluting stent versus the zotarolimus-eluting stent in a consecutive cohort of patients at a tertiary medical center
by: Jerin M, et al.
Published: (2012-04-01)

How real is a threat of late thrombosis for drug-eluting stents? Stent comparison and focus on everolimus
by: V. P. Lupanov, et al.
Published: (2009-10-01)

A randomized multicenter comparison of hybrid sirolimus-eluting stents with bioresorbable polymer versus everolimus-eluting stents with durable polymer in total coronary occlusion: rationale and design of the Primary Stenting of Occluded Native Coronary Arteries IV study
by: Teeuwen Koen, et al.
Published: (2012-12-01)

Long‐term (beyond 5 years) clinical impact of Xience everolimus‐eluting stent implantation
by: Hiroaki Matsuda, et al.
Published: (2021-09-01)

Comparison of everolimus-eluting and sirolimus-eluting coronary stents in 1-year clinical and angiographic follow-up: A retrospective cohort study
by: Ankur Gupta, et al.
Published: (2015-12-01)

Impact of the distance from the stent edge to the residual plaque on edge restenosis following everolimus-eluting stent implantation.
by: Masao Takahashi, et al.
Published: (2015-01-01)

Interleukin-6 kinetics can be useful for early treatment monitoring of severe bacterial sepsis and septic shock
by: Thomas Klag, et al.
Published: (2016-03-01)

Angioplasty and drug-eluting stent for vertebral artery stenosis
by: Nabil A Metwally, et al.
Published: (2018-01-01)